Cannabis Ruderalis

Content deleted Content added
Skoot13 (talk | contribs)
m <ref> clean up
Line 55: Line 55:
[[Category:Naphthoylindoles]]
[[Category:Naphthoylindoles]]
[[Category:Morpholines]]
[[Category:Morpholines]]
[[Category:Designer drugs]]





Revision as of 17:55, 27 November 2012

JWH-198
Identifiers
  • (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethanone
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H26N2O3
Molar mass414.495 g/mol g·mol−1
3D model (JSmol)
  • C4COCCN4CCn2cc(c5ccccc25)C(=O)c3c1ccccc1c(OC)cc3
 ☒NcheckY (what is this?)  (verify)

JWH-198 is a drug from the aminoalkylindole family which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-198 has a binding affinity at the CB1 receptor of 10nM, binding around four times more tightly than the parent compound JWH-200, which has no substitution on the naphthoyl ring.[1] It has been used mainly in molecular modelling of the cannabinoid receptors.[2][3]

See also

References

  1. ^ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
  2. ^ Eissenstat MA; et al. (1995). "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics". Journal of Medicinal Chemistry. 38 (16): 3094–105. doi:10.1021/jm00016a013. PMID 7636873. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)
  3. ^ Shim JY; et al. (1998). "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis". Journal of Medicinal Chemistry. 41 (23): 4521–32. doi:10.1021/jm980305c. PMID 9804691. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)


Leave a Reply